The fundraising campaign, through the Happy Capital crowdfunding platform was a success: the 400k€ objective was reached.
This fundraising campaign is still on-going until Nov 30th 2018 in order to raise additional funds for Peptinov’s clinical phase 1.
Peptinov launches a fundraising campaign, through the Happy Capital platform, which is among the top French investment crowdfunding platforms, in order to fund its clinical development (French language video).
Peptinov’s team was interviewed by Bordeaux TV (French language video):
Peptinov benefits from an interest-free loan (‘Aide à l’Innovation’) from BPI France (Banque Publique d’Investissement, the French government investment bank) to fund the pre-clinical studies for its anti-IL-6 immunotherapy.
René Azoulai joins Peptinov as its new CEO.
Peptinov’s anti-IL-6 is being evaluated in a regulatory toxicity study in cynomolgus monkeys. This study should be completed by September 2018.
Dr. Jean-Pierre Salles (Pharm.D) joins Peptinov as CTO. Dr. Salles is highly skilled in the fields of peptide synthesis and vaccine development.
Jan 20th 2016
Peptinov’s R&D team published an article in Scientific Reports (Nature Publishing Groupe), describing the immunogenicity and safety of Peptinov’s PPV-06 vaccine in monkeys, as well as a protective effect against the skin inflammation response to a DTH (Delayed Type-1 Hypersensitivity) reaction.
July 24th 2014
December 20th 2013
Roche’s new subcutaneous formulation of RoACTEMRA gains CHMP positive opinion in Europe for moderate to severe rheumatoid arthritis.
October 22nd 2013
Roche gains FDA approval for new subcutaneous formulation of ACTEMRA for use in adult patients living with moderately to severely active rheumatoid arthritis.
September 22nd 2013
Ablynx lands $840M AbbVie deal on next-gen Humira successor.
April 30th 2013
FDA approves ACTEMRA for children living with a rare form of arthritis.
March 1st 2013
Bruno Martin joins Peptinov as new CEO.
November 20th 2012
Peptinov is selected by Paris Biotech Santé for a relocation in the Cochin Santé Business Accelator. Relocation is to happen during the first quarter 2013.
August 3rd 2011
Roche’s RoACTEMRA approved in Europe for children living with a rare and severe form of arthritis.
April 18th 2011
FDA approves Actemra for the treatment of Systemic Juvenile Idiopathic Arthritis (SJIA).
June 10th 2010
Peptinov’s labs are relocated inside the campus of Cochin Hospital, Paris.
January 11th, 2010
FDA approves Actemra (Roche) for the treatment of moderately to severely active rheumatoid arthritis.